CytomX Therapeutics (CTMX) Projected to Post Quarterly Earnings on Thursday

CytomX Therapeutics (NASDAQ:CTMX) is anticipated to announce its Q4 2025 results before the market opens on Thursday, March 5th. Analysts expect CytomX Therapeutics to post earnings of ($0.08) per share and revenue of $7.3250 million for the quarter. Individuals may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Thursday, March 5, 2026 at 5:00 PM ET.

CytomX Therapeutics Stock Up 6.3%

NASDAQ:CTMX opened at $5.78 on Thursday. The stock has a market capitalization of $979.98 million, a price-to-earnings ratio of 14.46 and a beta of 2.44. CytomX Therapeutics has a 52 week low of $0.40 and a 52 week high of $6.35. The firm has a 50 day moving average of $5.00 and a 200 day moving average of $3.77.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on CTMX. Wall Street Zen lowered CytomX Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, November 8th. Guggenheim assumed coverage on CytomX Therapeutics in a research report on Tuesday, January 20th. They set a “buy” rating and a $10.00 target price on the stock. Barclays raised their price target on CytomX Therapeutics from $8.00 to $10.00 and gave the stock an “overweight” rating in a report on Wednesday, February 4th. Piper Sandler boosted their price target on CytomX Therapeutics from $6.50 to $10.00 and gave the stock an “overweight” rating in a research note on Tuesday, January 20th. Finally, Wedbush reaffirmed an “outperform” rating and issued a $6.00 price objective on shares of CytomX Therapeutics in a research report on Friday, November 7th. Seven investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $9.00.

Institutional Investors Weigh In On CytomX Therapeutics

A number of large investors have recently bought and sold shares of the company. Orbimed Advisors LLC purchased a new stake in shares of CytomX Therapeutics in the 2nd quarter valued at $19,208,000. Commodore Capital LP purchased a new position in shares of CytomX Therapeutics during the second quarter worth $17,462,000. Perceptive Advisors LLC acquired a new position in CytomX Therapeutics during the second quarter valued at $15,876,000. State Street Corp boosted its holdings in CytomX Therapeutics by 697.1% in the fourth quarter. State Street Corp now owns 5,140,931 shares of the biotechnology company’s stock valued at $21,900,000 after purchasing an additional 4,495,949 shares during the last quarter. Finally, Balyasny Asset Management L.P. purchased a new stake in CytomX Therapeutics in the second quarter valued at $6,505,000. Hedge funds and other institutional investors own 67.77% of the company’s stock.

About CytomX Therapeutics

CytomX Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation therapeutics based on its proprietary Probody® platform. The company engineers masked antibody prodrugs that remain inactive in healthy tissue but are selectively activated in the tumor microenvironment. This approach is designed to enhance the safety and tolerability of antibody-based therapies, particularly those targeting immuno-oncology pathways.

At the core of CytomX’s pipeline is Pacmilimab (CX-072), an anti–PD-L1 Probody therapeutic currently undergoing clinical evaluation for multiple solid tumor indications.